Observational Study to Assess Real-World Outcomes in Patients With Unresectable Liver Tumors Initiating Treatment With SIR-Spheres (Y-90 Resin Microspheres) (SIRtain Registry)

Status: Recruiting
Location: See all (9) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

This registry seeks to prospectively gather a large repository of comprehensive observational data reflecting routine use of SIR-Spheres in patients diagnosed with unresectable HCC or unresectable liver metastases from mCRC refractory to or intolerant to chemotherapy, in order to assess clinical response in a real-world setting and further validate the safe and appropriate use of SIR-Spheres

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age 18 years or older

• Confirmed diagnosis of:

• Unresectable hepatocellular carcinoma (HCC) Or

• Unresectable liver metastases from colorectal cancer (mCRC) refractory to or intolerant to chemotherapy

• Identified as a candidate for SIR-Spheres treatment as deemed appropriate during the normal course of practice

• Planned to receive SIR-Spheres treatment to the liver for the first time

• Provision of signed patient informed consent

Locations
Other Locations
France
Hôpital Beaujon
RECRUITING
Clichy
Hopital Henri Mondor
NOT_YET_RECRUITING
Créteil
Hospices Civils de Lyon HCL Centre Hospitalier Lyon-Sud
RECRUITING
Pierre-bénite
Spain
Hospital General Universitario Gregorio Marañon
NOT_YET_RECRUITING
Madrid
Hospital Universitario Puerta de Hierro - Majadahonda
NOT_YET_RECRUITING
Majadahonda
Hospital Clinico Universitario de Valencia
NOT_YET_RECRUITING
Valencia
United Kingdom
Hammersmith Hospital
NOT_YET_RECRUITING
London
Kings College Hospital
NOT_YET_RECRUITING
London
The Christie Hospital
NOT_YET_RECRUITING
Manchester
Contact Information
Primary
Janet Bell
jbell@sirtex.com
781-721-3840
Time Frame
Start Date: 2023-06-19
Estimated Completion Date: 2029-06
Participants
Target number of participants: 845
Treatments
Patients with unresectable HCC or unresectable liver metastases from mCRC
This cohort will include patients with unresectable HCC or unresectable liver metastases from mCRC refractory to or intolerant to chemotherapy, who have been prescribed selective internal radiation therapy (SIRT) with SIR-Spheres per medical decision.
Related Therapeutic Areas
Sponsors
Leads: Sirtex Medical

This content was sourced from clinicaltrials.gov